Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.69USD
3:59pm EST
Change (% chg)

$-0.01 (-1.43%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.73
Day's Low
$0.68
Volume
78,369
Avg. Vol
217,948
52-wk High
$6.24
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Trovagene Inc Says Company's Cash On Hand Should Be Sufficient For Company's Cash Needs Until July 2019
Wednesday, 24 Oct 2018 06:08pm EDT 

Oct 24 (Reuters) - Trovagene Inc ::TROVAGENE INC SAYS COMPANY'S CASH ON HAND SHOULD BE SUFFICIENT FOR COMPANY'S CASH NEEDS UNTIL JULY 2019 - SEC FILING.TROVAGENE INC SAYS COMPANY EXPECTS QUARTERLY BURN RATE TO INCREASE TO $5.0 MILLION PER QUARTER IN 2020.TROVAGENE INC SAYS IN THE FUTURE MAY LOOK TO RAISE AN ADDITIONAL $10 MILLION-$15 MILLION TO FUND ITS CASH NEEDS TO Q1 OF 2020.  Full Article

Trovagene Announces Exclusive License Agreement With MIT
Wednesday, 3 Oct 2018 08:30am EDT 

Oct 3 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH MIT FOR COMBINATION THERAPY OF ANTI-ANDROGENS AND POLO-LIKE KINASE INHIBITORS IN PROSTATE CANCER.TROVAGENE INC - AGREEMENT COVERS RIGHTS TO DEVELOP COMBINATION THERAPIES AND IDENTIFIED PREDICTIVE CLINICAL BIOMARKER ACROSS CANCER TYPES.  Full Article

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1B/2 Acute Myeloid Leukemia Trial
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES ACTIVATION OF SECOND CLINICAL TRIAL SITE IN PHASE 1B/2 ACUTE MYELOID LEUKEMIA (AML) TRIAL FOR PCM-075.TROVAGENE INC - ACTIVATION OF SECOND CLINICAL TRIAL SITE FOR ITS PHASE 1B/2 MULTICENTER TRIAL OF PCM-075 IN PATIENTS WITH AML.  Full Article

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Trovagene Inc ::TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.TROVAGENE INC - ‍LOOKING FORWARD TO A DECISION FROM FDA PERMITTING STUDY TO PROCEED, INITIATING MCRPC CLINICAL TRIAL IN PROSTATE CANCER IN 2018​.  Full Article

Trovagene Inc updates on clinical trial for PCM-075
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Trovagene Inc ::Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075.Trovagene Inc - ‍activation of its clinical trial site for its phase 1B/2 multicenter trial of PCM-075 in patients with AML​.Trovagene Inc - ‍trial will enroll subjects in phase 1B who have relapsed or have resistant disease to no more than three prior regimens​.  Full Article

TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12
Thursday, 9 Nov 2017 10:18am EST 

Nov 9 (Reuters) - Trovagene Inc ::Q3 LOSS PER SHARE $0.12.‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​.  Full Article

Trovagene files for offering of up to $17.5 mln- SEC filing
Wednesday, 25 Oct 2017 05:01pm EDT 

Oct 25 (Reuters) - Trovagene Inc : :Trovagene Inc files for offering of up to $17.5 million - SEC filing.  Full Article

Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Trovagene Inc :Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML).Trovagene - initiating Phase 1b/2 open-label trial to evaluate safety & anti-leukemic activity of PCM-075 in combination with standard-of-care in patients with AML​.  Full Article